Skip to main content

GD2 CAR T cells

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)

  • RegistryNCT04196413
  • PhasePhase 1
  • StatusRecruiting
  • ConditionGlioma of Spinal Cord
  • SponsorStanford University
How GD2 CAR T cells worksNCT041964134 min

What the film says

Read the transcript

In the middle of the brain stem there is a bulge called the pons. Everything that keeps you alive without your attention runs through it. Breathing, heart rate, the nerves for swallowing and speaking and moving your eyes.

Diffuse intrinsic pontine glioma grows there. About three hundred children in the United States are diagnosed each year, most of them between five and ten years old. The tumor does not sit in a lump. It grows woven through the pons, so it cannot be taken out, because there is nothing to take out without taking the child's breathing with it. Radiation helps for a while. Half of these children live about eleven months, and fewer than one in a hundred are alive five years later. It is the leading cause of brain cancer death in children.

For decades, nothing added to radiation changed that.

Then a lab at Stanford went looking for a handle. Nearly eight in ten of these tumors carry one tiny change. In histone H three, the spool that DNA winds around, a single amino acid is swapped. That one swap scrambles the instructions that tell a cell which genes to read. And it appears to switch on the enzymes that build a molecule called G D two, a sugar and fat structure that sits on the outside of the cell.

Every tumor sample they tested was covered in it. Healthy brain was not. They had found a flag.

So how do you attack a flag on a cell inside a brain stem? Not with a drug. With a cell.

Take the patient's own T cells, the immune system's hunters. In the lab, give them a new receptor: an outer piece that grips G D two, wired to the machinery that tells a T cell to kill. That is a C A R T cell, a living drug. It takes about a week to make.

The first infusion goes into a vein. Later doses go somewhere unusual, straight into the fluid that bathes the brain, through a small port under the scalp. That port matters twice over, because when the T cells reach the tumor and start working, the swelling arrives in the tightest possible place. The team named the problem and built a routine for it. Watch the pressure, drain fluid through the same port, treat the swelling. So far, in every patient, it has reversed.

Thirteen children and young adults enrolled in the first part of the trial, and eleven were treated. Nine of the eleven improved, in how they felt, on their scans, or both. Four tumors shrank by half or more, and one disappeared. That young man is now more than four years past his diagnosis and still getting infusions. A five-year-old regained the use of her hand and grew two inches. Most of the others, in time, got worse.

Cautious optimism is the phrase the researchers use, and they mean both words. They have since found part of the reason the effect fades. Patients' immune systems learn to attack the engineered receptor itself.

The trial is still open at Stanford, now for ages two to sixty, testing versions designed to last longer. It is led by Michelle Monje. The questions are still safety and dose.

Everything in this film comes from the published record, and it is not medical advice.

Sources behind this film

Show 4 more sources

The drug

What is being tested.

Autologous T-Cells transduced with retroviral vector (14g2a-CD8.BB.z.iCasp9) expressing GD2-chimeric antigen receptor

Fludarabine 30 mg/m2 per day IV for days -4, -3, -2

Primary Objectives: * Determine the feasibility of manufacturing autologous T cells transduced with 14g2a-CD8-BBz-iCasp9 retroviral vector expressing GD2 Chimeric Antigen Receptor (GD2CART) for administration in subjects with H3K27M-mutant diffuse midline glioma (DMG) using a retroviral vector and dasatinib in the Miltenyi CliniMACS Prodigy® system. * Assess the safety and identify the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), route and schedule of GD2CART and lymphodepleting chemotherapy in subjects with H3K27M-mutant DMG. * Assess the safety of the MTD/RP2D, route and schedule of GD2CART in expansion cohorts of subjects with H3K27M-mutant DMG.

The study

How the trial runs.

The primary purpose of this study is to test whether CAR T cells targeting GD2 (GD2CART) can be successfully made and safely given to children and adults with H3K27M-mutant diffuse midline glioma (DMG). Eligible subjects may have DMG arising in the pons (called difuse intrinisic pontine glioma, DIPG), the spinal cord, or other areas of the brain such as a thalamus

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Disease Status: Diagnosis of H3K27M mutant diffuse midline glioma (DMG)
  • H3K27M or H3K27I mutation. Confirmed by CLIA test.
  • Age: Greater than or equal to 2 year of age and less than or equal to 60 years of age.
  • At least 4 weeks following completion of standard upfront radiation therapy.
  • At least 3 weeks post chemotherapy or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy, except for systemic inhibitory/stimulatory immune checkpoint therapy that requires 3 months.
  • Dordaviprone (Modeyso), previously known as ONC201, may be taken as prior therapy but - just as with other anti-cancer medications - administration must cease at least 5 half-lives prior to enrollment

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.